Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Resveratrol use in metabolic syndrome.

Literature DB >> 25229675

Resveratrol use in metabolic syndrome.

Andrew A Bremer¹.

Abstract

Entities: Chemical Disease

Mesh：

Substances：
Insulin
Stilbenes

Year: 2014 PMID： 25229675 PMCID： PMC4251086 DOI： 10.1089/met.2014.1505

Source DB: PubMed Journal: Metab Syndr Relat Disord ISSN： 1540-4196 Impact factor: 1.894

× No keyword cloud information.

20 in total

1. Resveratrol ameliorates aging-related metabolic phenotypes by inhibiting cAMP phosphodiesterases.

Authors: Sung-Jun Park; Faiyaz Ahmad; Andrew Philp; Keith Baar; Tishan Williams; Haibin Luo; Hengming Ke; Holger Rehmann; Ronald Taussig; Alexandra L Brown; Myung K Kim; Michael A Beaven; Alex B Burgin; Vincent Manganiello; Jay H Chung
Journal: Cell Date: 2012-02-03 Impact factor: 41.582

2. The "metabolic winter" hypothesis: a cause of the current epidemics of obesity and cardiometabolic disease.

Authors: Raymond J Cronise; David A Sinclair; Andrew A Bremer
Journal: Metab Syndr Relat Disord Date: 2014-06-11 Impact factor: 1.894

3. Safety and metabolic outcomes of resveratrol supplementation in older adults: results of a twelve-week, placebo-controlled pilot study.

Authors: Stephen D Anton; Chelsea Embry; Michael Marsiske; Xiaomin Lu; Hani Doss; Christiaan Leeuwenburgh; Todd M Manini
Journal: Exp Gerontol Date: 2014-05-24 Impact factor: 4.032

Review 4. Small molecule SIRT1 activators for the treatment of aging and age-related diseases.

Authors: Basil P Hubbard; David A Sinclair
Journal: Trends Pharmacol Sci Date: 2014-01-16 Impact factor: 14.819

5. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan.

Authors: Konrad T Howitz; Kevin J Bitterman; Haim Y Cohen; Dudley W Lamming; Siva Lavu; Jason G Wood; Robert E Zipkin; Phuong Chung; Anne Kisielewski; Li-Li Zhang; Brandy Scherer; David A Sinclair
Journal: Nature Date: 2003-08-24 Impact factor: 49.962

6. Evidence for a common mechanism of SIRT1 regulation by allosteric activators.

Authors: Basil P Hubbard; Ana P Gomes; Han Dai; Jun Li; April W Case; Thomas Considine; Thomas V Riera; Jessica E Lee; Sook Yen E; Dudley W Lamming; Bradley L Pentelute; Eli R Schuman; Linda A Stevens; Alvin J Y Ling; Sean M Armour; Shaday Michan; Huizhen Zhao; Yong Jiang; Sharon M Sweitzer; Charles A Blum; Jeremy S Disch; Pui Yee Ng; Konrad T Howitz; Anabela P Rolo; Yoshitomo Hamuro; Joel Moss; Robert B Perni; James L Ellis; George P Vlasuk; David A Sinclair
Journal: Science Date: 2013-03-08 Impact factor: 47.728

7. Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes.

Authors: Jill C Milne; Philip D Lambert; Simon Schenk; David P Carney; Jesse J Smith; David J Gagne; Lei Jin; Olivier Boss; Robert B Perni; Chi B Vu; Jean E Bemis; Roger Xie; Jeremy S Disch; Pui Yee Ng; Joseph J Nunes; Amy V Lynch; Hongying Yang; Heidi Galonek; Kristine Israelian; Wendy Choy; Andre Iffland; Siva Lavu; Oliver Medvedik; David A Sinclair; Jerrold M Olefsky; Michael R Jirousek; Peter J Elliott; Christoph H Westphal
Journal: Nature Date: 2007-11-29 Impact factor: 49.962

8. Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans.

Authors: Silvie Timmers; Ellen Konings; Lena Bilet; Riekelt H Houtkooper; Tineke van de Weijer; Gijs H Goossens; Joris Hoeks; Sophie van der Krieken; Dongryeol Ryu; Sander Kersten; Esther Moonen-Kornips; Matthijs K C Hesselink; Iris Kunz; Vera B Schrauwen-Hinderling; Ellen Blaak; Johan Auwerx; Patrick Schrauwen
Journal: Cell Metab Date: 2011-11-02 Impact factor: 27.287

9. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice.

Authors: David E Harrison; Randy Strong; Zelton Dave Sharp; James F Nelson; Clinton M Astle; Kevin Flurkey; Nancy L Nadon; J Erby Wilkinson; Krystyna Frenkel; Christy S Carter; Marco Pahor; Martin A Javors; Elizabeth Fernandez; Richard A Miller
Journal: Nature Date: 2009-07-08 Impact factor: 49.962

10. A molecular mechanism for direct sirtuin activation by resveratrol.

Authors: Melanie Gertz; Giang Thi Tuyet Nguyen; Frank Fischer; Benjamin Suenkel; Christine Schlicker; Benjamin Fränzel; Jana Tomaschewski; Firouzeh Aladini; Christian Becker; Dirk Wolters; Clemens Steegborn
Journal: PLoS One Date: 2012-11-21 Impact factor: 3.240

8 in total

Review 1. Metabolic syndrome: pathophysiology, management, and modulation by natural compounds.

Authors: Yogita Rochlani; Naga Venkata Pothineni; Swathi Kovelamudi; Jawahar L Mehta
Journal: Ther Adv Cardiovasc Dis Date: 2017-06-22

2. Potential Involvement of Peripheral Leptin/STAT3 Signaling in the Effects of Resveratrol and Its Metabolites on Reducing Body Fat Accumulation.

Authors: Andrea Ardid-Ruiz; Maria Ibars; Pedro Mena; Daniele Del Rio; Begoña Muguerza; Cinta Bladé; Lluís Arola; Gerard Aragonès; Manuel Suárez
Journal: Nutrients Date: 2018-11-14 Impact factor: 5.717

Resveratrol use in metabolic syndrome.

1. Resveratrol ameliorates aging-related metabolic phenotypes by inhibiting cAMP phosphodiesterases.

2. The "metabolic winter" hypothesis: a cause of the current epidemics of obesity and cardiometabolic disease.

3. Safety and metabolic outcomes of resveratrol supplementation in older adults: results of a twelve-week, placebo-controlled pilot study.

Review 4. Small molecule SIRT1 activators for the treatment of aging and age-related diseases.

5. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan.

6. Evidence for a common mechanism of SIRT1 regulation by allosteric activators.

7. Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes.

8. Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans.

9. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice.

10. A molecular mechanism for direct sirtuin activation by resveratrol.

Review 1. Metabolic syndrome: pathophysiology, management, and modulation by natural compounds.

2. Potential Involvement of Peripheral Leptin/STAT3 Signaling in the Effects of Resveratrol and Its Metabolites on Reducing Body Fat Accumulation.

Review 3. Anti-Inflammatory Effects of Resveratrol: Mechanistic Insights.

Review 4. The Effects of Resveratrol in the Treatment of Metabolic Syndrome.

Review 5. Nanoformulations of natural products for management of metabolic syndrome.

Review 6. Current Advances in the Use of Nanophytomedicine Therapies for Human Cardiovascular Diseases.

Review 7. Influence of Resveratrol on the Cardiovascular Health Effects of Chronic Kidney Disease.

Review 8. Metabolic Syndrome: Updates on Pathophysiology and Management in 2021.